

HIV Drugs Market Size to Surpass with a Growing CAGR of 3.7% by 2030, Trends, Growth Strategies and Competitive Analysis

Global HIV Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Distribution Channel, By Region And Segment Forecasts, 2023 - 2030

WASHINGTON, D.C, DISTRICT OF COLUMBIA, UNITED STATES, February 6, 2024 /EINPresswire.com/ --

According to a report by Vantage Market Research, The Global [HIV Drugs Market](#) size was US\$31.3 Billion in 2022. The market is expected to grow to US\$40.3 Billion By 2030 at a CAGR of 3.7% in the 2023-2030 period. The rise in CAGR is attributable to this

market's demand and growth, returning to pre-pandemic levels once the pandemic is over. The future outlook for the HIV Drugs market is positive. The market is expected to grow at a steady pace in the coming years, driven by the factors mentioned above. The development of new and more effective HIV Drugs, as well as the increasing availability of HIV treatment in developing

countries, are expected to be the key drivers of growth in the market.



Vantage Market Research
Report for HIV Drugs
Market- A Closer Look at the
Future of HIV Drugs"
Vantage Market Research

HIV, or Human Immunodeficiency Virus, is a chronic and life-threatening disease that attacks immune cells known as CD-4 cells, making the body susceptible to infections and other diseases. This has subsequently led to a surge in demand for HIV medications with high potency for the

treatment and management of the disorder. The increasing patient population, coupled with new product launches, is likely to fuel the market growth. Significant research and development, promotion of government-run awareness programs, the launch of new products, and increasing market penetration by key companies in developing regions are contributing to the market growth.



Get Access to Free Sample Research Report with Latest Industry Insights @ <https://www.vantagemarketresearch.com/hiv-drugs-market-2036/request-sample>

Market Dynamics

The increasing demand for HIV Drugs from the emerging markets, such as Asia-Pacific, Latin America, and the Middle East and Africa, where the burden of HIV infection and AIDS is high and the awareness and penetration of HIV Drugs is low. These regions offer significant growth opportunities for the market players, as they can tap into the large and untapped customer base, expand their distribution channels and partnerships, and offer affordable and customized HIV Drugs solutions.

The growing competition and consolidation in the HIV Drugs market, as the market is dominated by a few major players, such as Gilead Sciences, ViiV Healthcare, Merck, AbbVie, and Janssen, that account for over 80% of the market share. These players are engaged in mergers and acquisitions, product launches, research and development, and marketing strategies to gain a competitive edge and increase their market share. For instance, in 2020, ViiV Healthcare acquired Bristol-Myers Squibb's HIV research and development portfolio, and Merck acquired Themis Bioscience, a company developing a vaccine for HIV.

The impact of the COVID-19 pandemic on the HIV Drugs market, as the pandemic disrupted the supply chain, reduced the production and sales of HIV Drugs, and affected the HIV care services and procedures. The lockdowns and social distancing measures imposed by the governments also reduced the number of patient visits to the clinics and hospitals, and the demand for HIV Drugs. However, the market is expected to recover and resume its growth in the post-pandemic period, as the HIV Drugs market players adopt new strategies, such as online consultations, telemedicine, home delivery, and remote monitoring, to cope with the challenges and meet the customer needs.

Top Players in The Global HIV Drugs Market Report Scope:

- ViiV Healthcare (U.S.)
- Gilead Sciences Inc. (U.S.)
- Glaxo Smith Kline PLC (U.K.)
- Merck Sharp & Dohme Corp. (France)
- Bristol-Myers Squibb Company (U.S.)
- Janssen Pharmaceuticals Inc. (Johnson & Johnson) (Belgium)
- Boehringer Ingelheim International GmbH (Germany)
- AbbVie Inc. (U.S.)
- Genentech Inc. (F. Hoffmann-La Roche AG) (U.S.)
- Mylan N.V. (U.S.)

To Know an Additional List of Key Players, Request Here to Download a Free Report PDF Brochure: <https://www.vantagemarketresearch.com/hiv-drugs-market-2036/request-sample>

Top Trends

The increasing popularity of [generic](#) HIV Drugs, which are HIV Drugs that have the same active ingredients, dosage, strength, quality, and safety as the branded HIV Drugs, but are sold at a lower price. Generic HIV Drugs can increase the accessibility and affordability of HIV Drugs, especially for the low- and middle-income countries, where the cost of HIV Drugs is a major barrier to treatment. The generic HIV Drugs market is expected to grow significantly in the coming years, as the patents of several branded HIV Drugs are expiring, and the market players are launching new and improved generic HIV Drugs. For instance, in 2020, Mylan launched TLD, a generic version of a single-pill combination HIV drug, in 97 low- and middle-income countries, under a licensing agreement with Gilead Sciences.

The increasing integration of artificial intelligence (AI) and machine learning (ML) in HIV Drugs, which enable the HIV Drugs market players to provide personalized and customized solutions for the customers, based on their genetic, clinical, and behavioral data. AI and ML also enable the HIV Drugs market players to perform various functions, such as drug discovery, drug development, drug delivery, drug monitoring, and drug adherence, that can improve the efficiency and effectiveness of HIV Drugs, and enhance the customer satisfaction and loyalty.

The increasing adoption of preventive and prophylactic HIV Drugs, which are HIV Drugs that are used to prevent or reduce the risk of HIV infection, before or after exposure to HIV. Preventive and prophylactic HIV Drugs can be of two types: pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). PrEP is a daily pill that can be taken by people who are at high risk of HIV infection, such as men who have sex with men, sex workers, and injection drug users, to prevent HIV infection. PEP is a short-term treatment that can be taken by people who have been exposed to HIV, such as through sexual assault, needle stick injury, or condom breakage, to prevent HIV infection. The preventive and prophylactic HIV Drugs market is expected to grow rapidly in the future, as the market players are developing new and improved preventive and prophylactic HIV Drugs, that offer better efficacy, safety, and convenience to the users. For instance, in 2020, the FDA approved Descovy, a new PrEP drug, that has fewer side effects and higher potency than the existing PrEP drug, Truvada.

Top Report Findings

- By drug class, the combination HIV medicines segment dominated the market in 2022, accounting for 57.4% of the market share, and is expected to maintain its dominance during the forecast period. The combination HIV medicines segment can be further classified into Atripla, Complera, Stribild, Triumeq, Genvoya, Odefsey, Descovy, Biktarvy, and others. Among these, Biktarvy held the largest share in 2022, owing to its high demand, availability, and suitability for various types of HIV patients.

- By distribution channel, the hospital pharmacies segment dominated the market in 2022, accounting for 43.7% of the market share, and is expected to grow at a significant CAGR during the forecast period. The hospital pharmacies segment includes the facilities that provide HIV Drugs to the patients, under the prescription and supervision of the qualified and experienced physicians and pharmacists. The hospital pharmacies segment is preferred by the patients who require professional consultation, diagnosis, and treatment for their HIV infection.
- By region, North America dominated the global market with a share of 41.2% in 2022, and is expected to retain its leading position during the forecast period. The market growth in North America can be attributed to the high prevalence of HIV infection and AIDS, the high awareness and adoption of [HIV Drugs Industry](#), the presence of major market players, the favorable reimbursement policies, and the technological advancements in the region.

Buy Now this Premium Research Report at a Special Price Against the List Price @ <https://www.vantagemarketresearch.com/buy-now/hiv-drugs-market-2036/0>

Challenges

The emergence and spread of drug-resistant HIV strains, which are HIV strains that have developed mutations that make them resistant to one or more HIV Drugs, and reduce the effectiveness and durability of the HIV treatment. According to the WHO, about 19% of the people living with HIV who are receiving ART have drug-resistant HIV, and this proportion is expected to increase in the future. The emergence and spread of drug-resistant HIV strains limit the treatment options and outcomes for the HIV patients, and pose a threat to the public health and the HIV Drugs market.

The side effects and adverse reactions of HIV Drugs, which are the unwanted and harmful effects that occur due to the use of HIV Drugs, and affect the quality of life and adherence of the HIV patients. Some of the common side effects and adverse reactions of HIV Drugs include nausea, vomiting, diarrhea, headache, fatigue, rash, liver toxicity, kidney damage, bone loss, and lactic acidosis. The side effects and adverse reactions of HIV Drugs may vary depending on the type, dose, and duration of the HIV Drugs, and the individual characteristics of the HIV patients, such as age, gender, weight, and genetic factors. The side effects and adverse reactions of HIV Drugs may also interact with other medications, supplements, or substances that the HIV patients may use, and cause more serious complications.

The stigma and discrimination associated with HIV infection and AIDS, which are the negative attitudes and behaviors that people have towards the people living with HIV or AIDS, and affect their access to and quality of HIV care and treatment. According to the UNAIDS, about 75% of the people living with HIV reported experiencing some form of stigma or discrimination in 2020, and about 20% of them reported being denied health care or receiving poor quality health care because of their HIV status. The stigma and discrimination associated with HIV infection and

AIDS may also affect the mental and emotional health of the HIV patients, and lead to depression, anxiety, isolation, and suicidal thoughts.

Get a Access To HIV Drugs Industry Real-Time Data @
<https://www.vantagemarketresearch.com/vantage-point>

Opportunities

The development and adoption of novel and innovative HIV Drugs, which are HIV Drugs that have new mechanisms of action, targets, or delivery methods, and offer better efficacy, safety, and convenience to the patients. For instance, some novel and innovative HIV Drugs that are in the pipeline or under development include lenacapavir, a long-acting injectable HIV drug that targets the capsid protein of HIV, islatravir, an oral HIV drug that inhibits the reverse transcriptase enzyme of HIV, and ABX464, an oral HIV drug that blocks the replication of HIV.

The expansion and diversification of the HIV Drugs market, as the market players can explore new and untapped segments and niches of the HIV Drugs market, such as the women, children, and key populations segments, and offer specialized and customized HIV Drugs solutions for these segments. For instance, the women segment requires HIV Drugs that are suitable for their reproductive health and pregnancy, the children segment requires HIV Drugs that are appropriate for their growth and development, and the key populations segment, such as men who have sex with men, sex workers, and injection drug users, requires HIV Drugs that are accessible and acceptable for their specific needs and preferences.

The increasing collaboration and partnership among the HIV Drugs market players, as the market players can benefit from the synergies, resources, and expertise of each other, and offer better and more comprehensive HIV Drugs solutions to the customers. For instance, the market players can collaborate and partner with the HIV research and development organizations, such as the International AIDS Vaccine Initiative (IAVI), the International Partnership for Microbicides (IPM), and the HIV Prevention Trials Network (HPTN), to conduct clinical trials and studies for the development and evaluation of new and improved HIV Drugs, and with the HIV advocacy and support groups, such as the AIDS Healthcare Foundation (AHF), the Global Network of People Living with HIV (GNP+), and the Treatment Action Group (TAG), to raise awareness and mobilize resources for the HIV Drugs.

Key Questions Answered in the Report

- Q. What are the key drivers, restraints, opportunities, and challenges of the HIV Drugs market?
- Q. What are the current and future trends of the HIV Drugs market?
- Q. What are the market size, share, growth rate, and forecast of the HIV Drugs market by drug class, distribution channel, and region?
- Q. Who are the major players in the HIV Drugs market, and what are their strategies, products, and competitive advantages?

Q. How is the COVID-19 pandemic affecting the HIV Drugs market, and what are the post-pandemic scenarios and outlooks for the market?

Q. What are the regulatory and ethical issues and implications of the HIV Drugs market?

Q. What are the customer needs, preferences, and expectations of the HIV Drugs market?

Q. What are the gaps and opportunities in the HIV Drugs market, and how can they be addressed and exploited?

Read Full Research Report with TOC @ <https://www.vantagemarketresearch.com/industry-report/hiv-drugs-market-2036>

Regional Analysis

North America currently represents one of the strongest economies leading to a well-established healthcare system. This acts as one of the key factors fostering the growth of the HIV Drugs market in the region. The US and Canadian governments are consistently investing funds on the research and development of safer and potent HIV Drugs. Moreover, higher diagnosis and treatment rate coupled with a surge in the adoption of advanced treatments act as another factor facilitating the growth of the HIV Drugs market in North America.

North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Among these, North America is the largest and most mature market for HIV Drugs, followed by Europe. However, Asia-Pacific is the fastest-growing and most promising market for HIV Drugs, owing to the large and increasing population, the high burden of HIV infection and AIDS, the low penetration and awareness of HIV Drugs, the improving economic and healthcare conditions, and the growing presence and expansion of the market players in the region. Antiretroviral drugs have played a major role in improving survival rates and the quality of life of HIV patients. These drugs help the immune system to keep the levels of the virus to a minimum level and prevent infections, leading to the prolonged life expectancy in patients. Antiretrovirals, when taken in the right combination can result in immune reconstitution, restore health, and prevent the development of AIDS and AIDS-related conditions.

Check Out More Research Reports:

□ Salicylic acid Market <https://www.vantagemarketresearch.com/industry-report/salicylic-acid-market-2389>

□ Glycolic Acid <https://www.vantagemarketresearch.com/industry-report/glycolic-acid-market-2380>

□ Peptide Synthesis Market <https://www.vantagemarketresearch.com/industry-report/peptide-synthesis-market-2379>

□ Cannabis Edibles Market <https://www.vantagemarketresearch.com/industry-report/cannabis-edibles-market-2405>

□ sustainable tourism Market <https://www.vantagemarketresearch.com/industry-report/sustainable-tourism-market-2406>

- resin Market <https://www.vantagemarketresearch.com/industry-report/resin-market-2407>
- Healthcare Biometrics Market : <https://www.linkedin.com/pulse/healthcare-biometrics-market-size-share-trends-analysis-hancock/>
- Medical Device Packaging Market : <https://www.linkedin.com/pulse/medical-device-packaging-market-size-share-trends-analysis-hancock/>
- Population Health Management Market : <https://www.linkedin.com/pulse/population-health-management-market-size-share-trends-ashley-hancock/>

Eric Kunz

Vantage Market Research

+1 202-380-9727

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/686513267>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.